Edition:
India

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

16.71USD
1:30am IST
Change (% chg)

$0.67 (+4.18%)
Prev Close
$16.04
Open
$16.00
Day's High
$16.94
Day's Low
$15.86
Volume
367,566
Avg. Vol
435,824
52-wk High
$16.94
52-wk Low
$1.94

Latest Key Developments (Source: Significant Developments)

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation For AXS-05 For The Treatment Of Major Depressive Disorder
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR AXS-05 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.  Full Article

Axsome Therapeutics's Major Depressive Disorder Treatment Meets Main Goal In Mid-stage Trial
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-05 ACHIEVES PRIMARY ENDPOINT IN PHASE 2 TRIAL IN MAJOR DEPRESSIVE DISORDER.AXSOME THERAPEUTICS - DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN MADRS SCORES COMPARED TO ACTIVE COMPARATOR (P<0.001 ON PRIMARY ENDPOINT).AXSOME THERAPEUTICS INC - AXS-05 MET PRESPECIFIED PRIMARY ENDPOINT.AXSOME THERAPEUTICS INC - AXS-05 WAS SAFE AND WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS.AXSOME THERAPEUTICS-AXS-05 WAS SUPERIOR TO BUPROPION ON MULTIPLE SECONDARY ENDPOINTS, WITH STATISTICALLY SIGNIFICANT EFFECTS DEMONSTRATED ON MOST.AXSOME THERAPEUTICS INC - TOPLINE RESULTS OF ONGOING PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION, ANTICIPATED LATER THIS QUARTER.AXSOME - RAPID IMPROVEMENT IN DEPRESSIVE SYMPTOMS SHOWING STATISTICALLY SIGNIFICANT SUPERIORITY OVER ACTIVE COMPARATOR WITHIN 1ST WEEK SEEN IN STUDY.AXSOME THERAPEUTICS INC - IMPROVEMENT WITH AXS-05 VERSUS ACTIVE COMPARATOR SEEN ON MULTIPLE SECONDARY ENDPOINTS SEEN IN STUDY.  Full Article

Axsome Therapeutics Qtrly Loss Per Share $0.31
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.FINAL PHASE 3 RESULTS OF AXS-05 IN TREATMENT RESISTANT DEPRESSION NOW ANTICIPATED IN 1Q 2019.FINAL PHASE 2 RESULTS OF AXS-05 IN MAJOR DEPRESSIVE DISORDER ANTICIPATED AROUND YEAR-END 2018.PHASE 2/3 INTERIM ANALYSIS RESULTS OF AXS-05 IN ALZHEIMER'S DISEASE AGITATION ANTICIPATED IN 4Q 2018.PHASE 3 TRIAL OF AXS-07 IN ACUTE MIGRAINE ANTICIPATED TO START IN 4Q 2018 TO 1Q 2019.PHASE 2 TRIAL OF AXS-12 IN NARCOLEPSY ANTICIPATED TO START IN 4Q 2018.QTRLY LOSS PER SHARE $0.31.Q3 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.  Full Article

Axsome Therapeutics Initiates Phase 2 Trial Of Axs-05 In Major Depressive Disorder
Tuesday, 5 Jun 2018 

June 5 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS INITIATES PHASE 2 TRIAL OF AXS-05 IN MAJOR DEPRESSIVE DISORDER.AXSOME THERAPEUTICS INC - FIRST PATIENT ENROLLED IN ASCEND STUDY.AXSOME THERAPEUTICS INC - TOPLINE RESULTS FROM ASCEND TRIAL ARE EXPECTED IN SECOND HALF OF 2018.  Full Article

Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19
Tuesday, 8 May 2018 

May 8 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.19.AT MARCH 31, 2018, AXSOME HAD $26.6 MILLION OF CASH COMPARED TO $34.0 MILLION OF CASH AT DECEMBER 31, 2017.BELIEVES CURRENT CASH WILL BE SUFFICIENT TO FUND OPERATIONS, BASED ON CURRENT OPERATING PLANS, INTO Q3 OF 2019.  Full Article

Axsome Therapeutics Says Independent Committee Recommends Continuation Of Depression Trial
Thursday, 26 Apr 2018 

April 26 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS OF STRIDE-1 PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION.AXSOME THERAPEUTICS INC - SECOND INTERIM ANALYSIS ANTICIPATED SECOND HALF OF 2018 FOR EFFICACY.AXSOME THERAPEUTICS INC - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TRIAL CONTINUATION.AXSOME THERAPEUTICS INC - IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION FROM STUDY AND INDICATED AXS-05 APPEARED SAFE AND WELL-TOLERATED.  Full Article

Axsome Therapeutics Reports Q4 Loss Per Share $0.31
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.31.AXSOME THERAPEUTICS - BELIEVES CASH AT DEC 31, 2017 TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO Q3 2019.AT DECEMBER 31, 2017, AXSOME HAD $34.0 MILLION OF CASH COMPARED TO $36.6 MILLION OF CASH AT DECEMBER 31, 2016.  Full Article

Axsome Collaborates With A Nicotine Addiction Research Center For Phase 2 Trial Of AXS-05 In Smoking Cessation
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS COLLABORATES WITH WORLD-LEADING NICOTINE ADDICTION RESEARCH CENTER FOR PHASE 2 TRIAL OF AXS-05 IN SMOKING CESSATION.AXSOME THERAPEUTICS - ‍ENTERED RESEARCH COLLABORATION WITH DUKE UNIVERSITY TO EVALUATE AXS-05 IN A PHASE 2 CLINICAL TRIAL IN SMOKERS ATTEMPTING TO QUIT​.AXSOME THERAPEUTICS INC - ‍PHASE 2 TRIAL INITIATION ANTICIPATED IN Q1 OF 2018 FOR AXS-05​.  Full Article

Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Axsome Therapeutics Inc ::SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING.  Full Article

Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE.AXSOME THERAPEUTICS INC - ‍PHASE 3 TRIAL ANTICIPATED IN 2018​.AXSOME THERAPEUTICS INC - AXS-07 HAS ‍POTENTIAL FOR "SUPERIOR" EFFICACY AS COMPARED TO CURRENT TREATMENTS​.AXSOME THERAPEUTICS INC - ‍U.S. FDA PRE-INVESTIGATIONAL NEW DRUG APPLICATION​ MEETING WRITTEN GUIDANCE RECEIVED.  Full Article